Tags

Type your tag names separated by a space and hit enter

Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma.
Clin Ther 1995 Jan-Feb; 17(1):2-11; discussion 1CT

Abstract

Asthma results from complex interactions among inflammatory cells, mediators, and the cells and tissues resident in the airways and is characterized by airway obstruction, airway inflammation, and airway hyperresponsiveness. Treatment of asthma should address not only the airway obstruction but also the chronic inflammation that may lead to hyperresponsiveness. In Japan, where the death rate from asthma has not increased despite increasing numbers of patients, treatment of bronchial asthma relies on the use of oral prophylactic antiasthma drugs, such as thromboxane synthetase inhibitors. Thromboxanes may facilitate the effect of acetylcholine on the airways and may be involved in hyperresponsiveness. Experiments using animal models have shown that thromboxane synthetase inhibitors have prevented increased airway reactivity after exposure to allergens and irritants. Double-blind clinical trials have shown that treatment with the thromboxane A2 synthetase inhibitor ozagrel hydrochloride significantly reduced the need for concomitant steroid therapy, compared with treatment with azelastine hydrochloride. This review discusses the role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma.

Authors+Show Affiliations

Department of Dermatology, Gunma University School of Medicine, Maebashi, Japan.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

7758058

Citation

Kurosawa, M. "Role of Thromboxane A2 Synthetase Inhibitors in the Treatment of Patients With Bronchial Asthma." Clinical Therapeutics, vol. 17, no. 1, 1995, pp. 2-11; discussion 1.
Kurosawa M. Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma. Clin Ther. 1995;17(1):2-11; discussion 1.
Kurosawa, M. (1995). Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma. Clinical Therapeutics, 17(1), pp. 2-11; discussion 1.
Kurosawa M. Role of Thromboxane A2 Synthetase Inhibitors in the Treatment of Patients With Bronchial Asthma. Clin Ther. 1995;17(1):2-11; discussion 1. PubMed PMID: 7758058.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma. A1 - Kurosawa,M, PY - 1995/1/1/pubmed PY - 1995/1/1/medline PY - 1995/1/1/entrez SP - 2-11; discussion 1 JF - Clinical therapeutics JO - Clin Ther VL - 17 IS - 1 N2 - Asthma results from complex interactions among inflammatory cells, mediators, and the cells and tissues resident in the airways and is characterized by airway obstruction, airway inflammation, and airway hyperresponsiveness. Treatment of asthma should address not only the airway obstruction but also the chronic inflammation that may lead to hyperresponsiveness. In Japan, where the death rate from asthma has not increased despite increasing numbers of patients, treatment of bronchial asthma relies on the use of oral prophylactic antiasthma drugs, such as thromboxane synthetase inhibitors. Thromboxanes may facilitate the effect of acetylcholine on the airways and may be involved in hyperresponsiveness. Experiments using animal models have shown that thromboxane synthetase inhibitors have prevented increased airway reactivity after exposure to allergens and irritants. Double-blind clinical trials have shown that treatment with the thromboxane A2 synthetase inhibitor ozagrel hydrochloride significantly reduced the need for concomitant steroid therapy, compared with treatment with azelastine hydrochloride. This review discusses the role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma. SN - 0149-2918 UR - https://www.unboundmedicine.com/medline/citation/7758058/Role_of_thromboxane_A2_synthetase_inhibitors_in_the_treatment_of_patients_with_bronchial_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0149-2918(95)80002-6 DB - PRIME DP - Unbound Medicine ER -